Building on our innovative approach, we will utilize the patient’s own blood cells—specifically, monocytes—as the foundational material for engineering macrophages tailored to modulate the immune response in asthma.

These cells will be isolated and cultured under precisely controlled laboratory conditions, allowing us to program them with anti-inflammatory properties before reintroducing them into the patient.

By harnessing the body’s own cellular machinery, this personalized therapy aims to provide long-lasting control over airway inflammation, reduce the frequency and severity of asthma attacks, and minimize the need for systemic medications.

This strategy could not only improve outcomes for individuals with severe, treatment-resistant asthma, but also pave the way for broader applications of cell-based therapies in other chronic inflammatory diseases.